Q-omics provides the consensus-scored RPS4Y2 profile across patient tissues and cancer cell-line models. RPS4Y2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Additionally, RPS4Y2 RNA expression shows 6,076 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, and STAD as cancer lineages where RPS4Y2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4Y2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4Y2 survival associations across molecular data types. RPS4Y2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4Y2 RNA expression–survival associations across cancer types. High RPS4Y2 expression shows unfavorable associations in STAD, UCEC, PAAD and SKCM, but favorable associations in BLCA and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for RPS4Y2 RNA expression.
This table shows molecular features associated with RPS4Y2 in patient tissues and cancer cell lines. In patient samples, RPS4Y2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS4Y2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
